Company / R&D Expense
Vistagen Therapeutics, Inc. R&D Expense History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$35.4M
FY2023
5-year range
$3.9M / $35.4M
FY2019-FY2023
Trend
+196.9%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 8 years, ranging from $3M in FY2014 to $35M in FY2023.
Based on SEC 10-K filings.
$35M in FY2023 with a 5-year CAGR of +46.7%.
Improved from $13M to $35M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +46.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +46.7%, indicating consistent growth.
- In FY2023, r&d expense increased 196.9% year-over-year.
- Lowest r&d expense in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $35.4M | +196.9% |
| FY2022 | $11.9M | -10.8% |
| FY2021 | $13.4M | +157.0% |
| FY2018 | $5.2M | +32.4% |
| FY2017 | $3.9M | +14.6% |
| FY2014 | $3.4M | -36.3% |
| FY2012 | $5.4M | +46.5% |
| FY2011 | $3.7M | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026